Abstract

BackgroundHeterologous production of natural products in Escherichia coli has emerged as an attractive strategy to obtain molecules of interest. Although technically feasible most of them are still constrained to laboratory scale production. Therefore, it is necessary to develop reasonable scale-up strategies for bioprocesses aiming at the overproduction of targeted natural products under industrial scale conditions. To this end, we used the production of the antibiotic valinomycin in E. coli as a model system for scalable bioprocess development based on consistent fed-batch cultivations.ResultsIn this work, the glucose limited fed-batch strategy based on pure mineral salt medium was used throughout all scales for valinomycin production. The optimal glucose feed rate was initially detected by the use of a biocatalytically controlled glucose release (EnBase® technology) in parallel cultivations in 24-well plates with continuous monitoring of pH and dissolved oxygen. These results were confirmed in shake flasks, where the accumulation of valinomycin was highest when the specific growth rate decreased below 0.1 h−1. This correlation was also observed for high cell density fed-batch cultivations in a lab-scale bioreactor. The bioreactor fermentation produced valinomycin with titers of more than 2 mg L−1 based on the feeding of a concentrated glucose solution. Valinomycin production was not affected by oscillating conditions (i.e. glucose and oxygen) in a scale-down two-compartment reactor, which could mimic similar situations in industrial bioreactors, suggesting that the process is very robust and a scaling of the process to a larger industrial scale appears a realistic scenario.ConclusionsValinomycin production was scaled up from mL volumes to 10 L with consistent use of the fed-batch technology. This work presents a robust and reliable approach for scalable bioprocess development and represents an example for the consistent development of a process for a heterologously expressed natural product towards the industrial scale.

Highlights

  • Heterologous production of natural products in Escherichia coli has emerged as an attractive strategy to obtain molecules of interest

  • Valinomycin is an NRP cyclodepsipeptide antibiotic that is naturally biosynthesized by several Streptomyces strains via the enzyme valinomycin synthetase, which belongs to the mRNA-independent assembly lines termed nonribosomal peptide synthetase (NRPS) [14,15,16]

  • We aim to develop a rational scale-up bioprocess route at the example of valinomycin production, which we believe provides a reasonable bioprocess development approach for realizing natural product production to meet the demand

Read more

Summary

Introduction

Heterologous production of natural products in Escherichia coli has emerged as an attractive strategy to obtain molecules of interest. It is necessary to develop reasonable scale-up strategies for bioprocesses aiming at the overproduction of targeted natural products under industrial scale conditions To this end, we used the production of the antibiotic valinomycin in E. coli as a model system for scalable bioprocess development based on consistent fed-batch cultivations. Natural products are of great significance because they are important sources for pharmaceuticals to treat human and animal diseases [1] These natural compounds include nonribosomal peptides (NRPs, e.g. vancomycin), Li et al Microb Cell Fact (2015) 14:83 well-characterized and genetically tractable host microorganisms [3,4,5,6,7,8,9,10,11,12]. Coexpression of the cognate type II thioesterase (TEII), which is encoded in the valinomycin gene cluster and responsible for regeneration of the NRPS activity, with Vlm and Vlm further improved valinomycin production to a final titer of 13 mg L−1 [19]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call